5 nurses who work on the same floor at Massachusetts hospital have brain tumors
A Boston-area hospital is investigating after five nurses who have worked on the same floor have developed brain tumors.
Mass General Brigham Newton-Wellesley Hospital said that in total, 11 employees from the fifth-floor maternity unit identified health concerns. Five had brain tumors, all of which are benign. Two of those have the most common, benign type — meningioma, according to the hospital in Newton, Massachusetts, which is about 10 miles west of Boston.
'The investigation found no environmental risks which could be linked to the development of a brain tumor,' the hospital's Jonathan Sonis, associate chief medical officer, and Sandy Muse, chief nursing officer, said in a statement.
The hospital said its investigation was completed in collaboration with government health and safety officials and it considered multiple possible sources. It ruled out disposable masks, the water supply, nearby x-rays, and chemotherapy treatment on the floor below, the hospital said.
'Based on these results, we can confidently reassure our dedicated team ... and all our patients that there is no environmental risk at our facility," the administrators said.
The Massachusetts Nurses Association, the union that bargains for nurses' compensation at Newton-Wellesley Hospital, said it will continue to investigate.
"Right now, the best way we can help is to complete an independent, scientific investigation," MNA spokesperson Joe Markman said in a statement Friday. "That effort is underway and may take additional weeks."
The union indicated that nurses came forward with workplace health concerns, which led to the discovery of those with tumors.
'The hospital only spoke to a small number of nurses, and their environmental testing was not comprehensive,' he said in his statement. 'The hospital cannot make this issue go away by attempting to provide a predetermined conclusion.'
A spokesperson for a state agency was unable to provide conclusive information on the matter by deadline. Federal occupational health and safety officials did not immediately respond to a request for comment.
The American Cancer Society says that in order to meet the definition of a cancer cluster, occurrences must be the same type, in the same area, with the same cause, and affecting a number of people that's "greater than expected" when a baseline for occurrences is established.
'Nearly 4 out of 10 people in the United States will develop cancer during their lifetimes," the society said on its cancer clusters webpage. "So, it's not uncommon for several people in a relatively small area to develop cancer around the same time."
This article was originally published on NBCNews.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Alys Pharmaceuticals announces CTA submission for ALY-301, the first mast cell selective c-Kit inhibitor for treatment of Cold Urticaria
ALY-301 is a first-in-class bispecific antibody targeting c-Kit and CD-203c with mast cell selectivity Designed to enable safe dosing in chronic conditions and deliver clinical proof-of concept in a Phase 1/1b study BOSTON and LAUSANNE, Switzerland, June 10, 2025 /PRNewswire/ -- Alys Pharmaceuticals, Inc. ("Alys"), an immune-dermatology focused company, today announces the submission of a Clinical Trial Application (CTA) to Germany's Paul-Ehrlich-Institut (PEI) to initiate a Phase 1/1b study of ALY-301 in healthy volunteers and patients suffering from Cold Urticaria, a subtype of Chronic Inducible Urticaria (CIndU). Cold Urticaria is a chronic skin disease where red, itchy wheals or hives appear after the skin is exposed to cold temperatures. It is a well-established clinical model for mast cell-mediated diseases in general, and chronic spontaneous urticaria in particular. Current and emerging solutions do not address the significant unmet medical needs experienced by patients. In conjunction with limited treatment options, the Urticaria market is projected to reach multiple billions within the next ten years. ALY-301 is the first mast cell-selective c-Kit inhibitor to enter the clinic. It is a cis-targeting bispecific antibody binding c-Kit and CD-203c, allowing selective targeting and depletion of mast cells over other c-Kit positive cells. This differentiated profile of ALY-301 is expected to offer a significantly improved safety profile over conventional c-Kit targeting agents and enable safe, chronic dosing in multiple mast-cell dependent diseases such as Chronic Urticaria. The trial will evaluate the safety and efficacy of ALY-301 at multiple sites across Germany. This CTA submission is the first clinical program to emerge from Alys' Granular platform, which is focused on the precise targeting of mast cell biology through advanced antibody engineering. Professor Brian Kim, Sol and Clara Kest Professor of Dermatology and Vice Chair of Research at Icahn School of Medicine at Mount Sinai and Head of Alys Pharmaceuticals Scientific Advisory Board, said: "ALY-301 offers a truly differentiated approach. It is the only c-Kit antibody designed to target activated mast cells while avoiding off-target effects. Unleashing the proven efficacy of c-Kit inhibition on mast cells, while sparing all other cell-types that have been associated with significant side effects, should result in a transformational drug profile for ALY-301 and could have a revolutionary impact on Chronic Urticaria and several other allergic indications." Professor Martin Metz, Professor of Dermatology at the Institute of Allergology at the Charité – Universitätsmedizin Berlin & Fraunhofer Institute for Translational Medicine and Pharmacology, Allergology and Immunology and Principal Investigator for ALY-301, commented: "The concept behind ALY-301, to enable safe and effective chronic dosing of a c-Kit agent through mast-cell selectivity, has been strongly supported across all non-clinical studies. It is very exciting to start the clinical journey today, especially since this first clinical trial will yield clinical outcomes from Urticaria patients." Thibaud Portal, Co-Founder and Chief Operating Officer of Alys Pharmaceuticals, added: "Recently, there has been intense attention to solving Urticaria and other allergic diseases, with keen interest in c-Kit targeting. Data have demonstrated the remarkable potency of the mode of action, but indiscriminate c-Kit targeting has been coupled with chronic safety challenges. ALY-301 is a first-in-class approach that combines the power of c-Kit inhibition with selectivity and safety. With its expected safety margin and broad applicability across multiple diseases, this marks another pivotal moment for Alys in our journey to bring innovative treatments to patients." This study marks the second major clinical milestone for Alys Pharmaceuticals. The Alys pipeline includes a diverse portfolio of assets targeting unmet needs in indications such as atopic dermatitis, chronic spontaneous urticaria, vitiligo, and systemic mastocytosis. The Company remains on track to deliver multiple clinical Proof-of-Concept (POC) readouts by 2027. About Alys PharmaceuticalsAlys Pharmaceuticals, Inc. ("Alys") is a Boston and Lausanne-based cutting edge pure-play immuno-dermatology company. Alys is backed by international investment firm Medicxi with $100M financing. Alys has a world class leadership team that brings together experts across dermatology and advanced scientific fields, including co-founders John Harris (UMass Chan Medical School), Brian Kim (Icahn School of Medicine at Mount Sinai), Lars French (LMU, Munich), Craig Mello (UMass Chan Medical School), Eric Deutsch (Gustave Roussy) and Mark Prausnitz (Georgia Institute of Technology). Alys is led by dermatology specialist, co-founder, and COO Thibaud Portal. Its pipeline includes programs targeting multiple dermatological indications, including atopic dermatitis, vitiligo, chronic urticaria, psoriasis and mastocytosis. The Company entered the clinic in Q1 2025 with the siRNA platform developed by its affiliate Aldena Therapeutics, which offers the potential for long-lasting treatments that could transform the dermatology treatment landscape and is now advancing its mastocyte-selective therapies developed by affiliate Granular Therapeutics. For further information, please visit View original content: SOURCE Alys Pharmaceuticals Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
New York Post
4 hours ago
- New York Post
NY state Senate approves doctor-assisted suicide bill, sends it to Hochul's desk for approval
ALBANY – State Senate Democrats passed highly controversial legislation that would allow terminally ill people to take their own lives with the help of doctors in a razor-thin vote Monday — leaving it up to Gov. Kathy Hochul whether to sign it into law. 'This is one of the great social reforms of our state,' state Sen. Brad Hoylman-Sigal (D-Manhattan), the bill's sponsor in the upper chamber, touted at a press conference earlier in the day Monday — putting the measure on the same tier as the legalization of gay marriage. 'This is about personal autonomy, this is about liberty, this is about exercising one's own freedom to control one's body,' Hoylman-Sigal continued. 3 The 'Medical Aid in Dying Act' passed the state senate Monday evening, meaning it only needs Gov. Kathy Hochul's signature to become law. Vaughn Golden The measure passed 35 to 27, with six Democrats – Senators April Baskin, Siela Bynoe, Cordelle Cleare, Monica Martinez, Roxanne Persaud, and Sam Sutton – voting against it. 'The governor will review the legislation,' a spokesperson for Hochul said. The bill's passage follows a years-long campaign that was fought tooth and nail by a diverse group of critics, including disability rights activists and the Catholic church, as well as many black and Orthodox Jewish communities. 'The Governor still has the opportunity to uphold New York's commitment to suicide prevention, protect vulnerable communities, and affirm that every life—regardless of disability, age, or diagnosis—is worthy of care, dignity, and protection,' The New York Alliance Against Assisted Suicide wrote in a statement following the vote. A Catholic group slammed the bill's passing as 'a dark day for New York' and also called on Hochul to refuse to sign it. 'For the first time in its history, New York is on the verge of authorizing doctors to help their patients commit suicide. Make no mistake – this is only the beginning, and the only person standing between New York and the assisted suicide nightmare unfolding in Canada is Governor Hochul,' Dennis Poust, Executive Director of the New York State Catholic Conference, wrote in a statement. 3 The state Senate voted 35-27 Monday night to legalize physician-assisted suicide for people with terminal illnesses. AP Ahead of the vote, the nearly three-hour debate on the Senate floor got emotional, with several lawmakers holding back tears as they explained their votes. Syracuse-area state Sen. Rachel May (D-Onondaga) shared the story of her late husband, who was receiving morphine in the final stages of his battle with cancer, which he eventually succumbed to at 32 years old. 'I don't know if the last largest dose he took also took his life, but I know that he died in peace,' May said. 'It isn't about controlling the disease or controlling the pain, it's about having control at the end of your life,' she said before voting in favor. Critics fear the legislation lacks critical safeguards over how doctors approve patients looking to receive the prescription for a lethal cocktail of drugs, such as a statutory waiting period, establishing clear chain of custody for the pills, mandating the doctor and recipient meet in-person, and requiring a disclosure that someone indeed used the drugs to take their own life. Under the bill, recipients would need approval from two doctors and a sign-off from two independent witnesses, after which they would receive a prescription for drugs they could use to take their life at a time of their choosing. 3 Gov. Kathy Hochul has not signaled whether she will sign the assisted suicide bill. Lev Radin/ZUMA / Doctors also do not have to conduct a mental health screening for each patient, but may refer a patient for one under the legislation. 'I don't think requesting end-of-life medication when an individual is suffering and in pain and dying suggests a mental health condition, if anything, I think it's quite rational,' Hoylman-Sigal said. Hoylman vowed the bill would not lead to such 'unintended consequences.' 'It was a professional organization that provided us crucial guidance, that helped us develop the state-of-the-art safeguards in this legislation that gave my colleagues and the general public, I believe, the assurance that there will not be unintended consequences,' he said. The legislation is referred to by its supporters as the 'Medical Aid in Dying' bill. 'The option of medical aid in dying provides comfort, allowing those who are dying to live their time more fully and peacefully until the end. I am profoundly grateful to Senate Majority Leader Stewart-Cousins for giving her conference the space to have this important and emotional discussion,' Corinne Carey, Senior Campaign Director of Compassion and Choices, the main group driving the effort to pass the bill, wrote in a statement.
CBS News
5 hours ago
- CBS News
Denver Fork Cancer event to fight cancer, raise awareness for patients one bite at a time
Fundraiser called Fork Cancer to take place in July in Denver Fundraiser called Fork Cancer to take place in July in Denver Fundraiser called Fork Cancer to take place in July in Denver In Colorado, about one-in-two men and two-in-five women will be diagnosed with some form of cancer in their lifetimes. It's a common disease in our state, with about 25,000 Coloradans diagnosed every year. American Cancer Society Cancer Action Network But Fork Cancer, hosted by the American Cancer Society Cancer Action Network, is helping fight cancer. American Cancer Society Cancer Action Network The party with a purpose features Denver fine culinary establishments while offering a variety of small plates, spirits and brews, and live entertainment acts. Ocular melanoma survivor Katie Doble will also share her powerful story of resilience. American Cancer Society Cancer Action Network You're invited to Fork Cancer, July 17th at 6:30pm at Mile High Station. CBS Colorado Anchor Mekialaya White will host the event. Tickets are available here.
